Complication prevention, red flags, adverse events, emergency readiness, and risk tradeoffs.
A comprehensive regulatory dossier mapping InMode's RF technology architecture (Morpheus8, BodyTite, FaceTite), FDA 510(k) clearances, and post-market safety…
A clinical evaluation of lipotropic MIC-B12 injections, examining the evidence for weight-loss claims, metabolic pathways, and safety profiles from public database…
A comprehensive regulatory dossier analyzing Merz Aesthetics' portfolio, Xeomin's BLA registration, Radiesse's and Belotero's PMA history, and Ultherapy PRIME's FDA…
An evidence-based clinical review of NAD+ IV therapy, analyzing the 2025 FDA Class I recall of GenoGenix lots, endotoxin contamination risks, and human clinical trial…
Emface pairs synchronized radiofrequency with HIFES facial-muscle stimulation. We break down what the FDA cleared it for, what the small manufacturer studies show, and…
Pseudofolliculitis barbae affects up to 83% of Black men who shave. We lay out the evidence ladder from shaving cessation to 1064 nm Nd:YAG laser hair removal for…
The FDA's proposed exclusion of semaglutide and tirzepatide from the 503B Bulks List will end industrial GLP-1 compounding in 2026. A guide to legal timelines and…
Plasma pens bypass FDA cosmetic reviews, but voluntary MAUDE databases reveal severe risks of atrophic scarring and hypopigmentation requiring costly laser corrections.
Chin implant (FWP) FDA MAUDE analysis: across 237 reports patient injury dominates and infection is the leading complication theme — with the caveats MAUDE demands.
FDA warnings on needle-free dermal filler devices (Hyaluron Pens). High-pressure jet injection carries severe risks of skin necrosis, permanent blindness, and clinical…